PCID2

Summary

PCID2 (PCI domain containing 2, HGNC:25653) is a protein-coding gene on chromosome 13q34, encoding PCI domain-containing protein 2 (Q5JVF3). Required for B-cell survival through the regulation of the expression of cell-cycle checkpoint MAD2L1 protein during B cell differentiation. It is a common-essential gene (DepMap: required in 96.5% of cancer cell lines).

This gene encodes a component of the TREX-2 complex (transcription and export complex 2), which regulates mRNA export from the nucleus. This protein regulates expression of Mad2 mitotic arrest deficient-like 1, a cell division checkpoint protein. This protein also interacts with and stabilizes Brca2 (breast cancer 2) protein. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 55795 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 113 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 96.5% of screened cell lines (common-essential)
• MANE Select transcript: NM_001127202

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25653
Approved symbol	PCID2
Name	PCI domain containing 2
Location	13q34
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11305
Ensembl gene	ENSG00000126226
Ensembl biotype	protein_coding
OMIM	613713
Entrez	55795

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 12 protein_coding, 9 protein_coding_CDS_not_defined

ENST00000246505, ENST00000337344, ENST00000375457, ENST00000375459, ENST00000375477, ENST00000375479, ENST00000462653, ENST00000462853, ENST00000463102, ENST00000473462, ENST00000475433, ENST00000480971, ENST00000484641, ENST00000491548, ENST00000493650, ENST00000622406, ENST00000925339, ENST00000952596, ENST00000952597, ENST00000952598, ENST00000952599

RefSeq mRNA: 14 — MANE Select: NM_001127202 NM_001127202, NM_001127203, NM_001258213, NM_001320655, NM_001320656, NM_001320657, NM_001320659, NM_001320660, NM_001353091, NM_001353092, NM_001353093, NM_001353094, NM_001353095, NM_018386

CCDS: CCDS58301, CCDS58302, CCDS9532

Canonical transcript exons

ENST00000337344 — 14 exons

Exon	Start	End
ENSE00001419101	113177536	113178287
ENSE00001898558	113208599	113208669
ENSE00003468541	113200427	113200516
ENSE00003497525	113197178	113197243
ENSE00003499188	113185485	113185560
ENSE00003526446	113190872	113190975
ENSE00003541041	113198191	113198264
ENSE00003554023	113196181	113196222
ENSE00003557919	113195071	113195125
ENSE00003571281	113180158	113180231
ENSE00003614870	113178966	113179089
ENSE00003615920	113184346	113184487
ENSE00003644620	113179917	113180042
ENSE00003675012	113181130	113181230

Expression profiles

Bgee: expression breadth ubiquitous, 282 present calls, max score 98.06.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.5998 / max 305.8048, expressed in 1808 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
138335	26.7353	1805
138328	1.1065	413
138330	0.4685	254
138329	0.1288	56
138325	0.0767	26
138334	0.0610	4
138331	0.0229	13

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	98.06	gold quality
secondary oocyte	CL:0000655	96.26	gold quality
left ovary	UBERON:0002119	95.42	gold quality
right ovary	UBERON:0002118	95.24	gold quality
left testis	UBERON:0004533	94.68	gold quality
adrenal tissue	UBERON:0018303	94.53	gold quality
right testis	UBERON:0004534	94.49	gold quality
endocervix	UBERON:0000458	94.42	gold quality
body of uterus	UBERON:0009853	94.16	gold quality
cerebellar hemisphere	UBERON:0002245	93.85	gold quality
cerebellar cortex	UBERON:0002129	93.76	gold quality
left uterine tube	UBERON:0001303	93.73	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.73	gold quality
ectocervix	UBERON:0012249	93.71	gold quality
granulocyte	CL:0000094	93.65	gold quality
right coronary artery	UBERON:0001625	93.63	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.63	gold quality
right uterine tube	UBERON:0001302	93.61	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	93.58	gold quality
testis	UBERON:0000473	93.53	gold quality
right adrenal gland cortex	UBERON:0035827	93.53	gold quality
ascending aorta	UBERON:0001496	93.50	gold quality
thoracic aorta	UBERON:0001515	93.48	gold quality
adenohypophysis	UBERON:0002196	93.47	gold quality
body of pancreas	UBERON:0001150	93.40	gold quality
heart left ventricle	UBERON:0002084	93.30	gold quality
descending thoracic aorta	UBERON:0002345	93.29	gold quality
right adrenal gland	UBERON:0001233	93.26	gold quality
left adrenal gland cortex	UBERON:0035825	93.24	gold quality
lower esophagus muscularis layer	UBERON:0035833	93.21	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.86
E-HCAD-29	no	625.45

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting PCID2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-330-3P	99.41	69.95	2521
HSA-MIR-410-3P	99.27	69.98	2457
HSA-MIR-223-5P	99.24	68.82	1206
HSA-MIR-4426	99.17	66.74	1949
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-7151-3P	99.04	69.72	2370
HSA-MIR-4662B	98.33	66.37	1163
HSA-MIR-4511	98.32	67.97	1500
HSA-MIR-4647	98.30	66.41	1139
HSA-MIR-6728-5P	97.79	66.33	891
HSA-MIR-3665	97.73	65.08	975
HSA-MIR-6791-3P	97.45	64.31	1123
HSA-MIR-6829-3P	97.45	64.31	1137
HSA-MIR-8069	97.05	66.79	718
HSA-MIR-4689	96.97	65.79	1209
HSA-MIR-454-5P	96.51	68.35	263
HSA-MIR-10A-3P	93.57	64.43	451

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 96.5% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 8)

• validated occurrence of an unusual TG 3’ splice site in intron 2 (PMID:17672918)
• Pcid2 is present in the CBP/p300-EID1 complex to control the switch balance of mouse and human embryonic stem cells through modulation of EID1 degradation. (PMID:24167073)
• First discovery of specific novel functions for PCID2 other than mRNA export and components of the TREX-2 complex serve alternative shared roles in the regulation of nuclear transport and cell cycle progression. (PMID:24291146)
• Data show that PCI domain-containing protein 2 (Pcid2) controls lymphoid lineage commitment through the regulation of Snf2-related CREBBP activator protein (SRCAP) remodelling activity. (PMID:29138493)
• Distinct effects on mRNA export factor GANP underlie neurological disease phenotypes and alter gene expression depending on intron content. (PMID:32202298)
• Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas. (PMID:34031538)
• A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML). (PMID:34625711)
• [PCID2 is highly expressed in gastric cancer and affects the prognosis by regulating cancer cell cycle and proliferation]. (PMID:38501418)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	pcid2	ENSDARG00000013802
mus_musculus	Pcid2	ENSMUSG00000038542
rattus_norvegicus	Pcid2	ENSRNOG00000025222
drosophila_melanogaster	PCID2	FBGN0036184
caenorhabditis_elegans		WBGENE00016171

Protein

Protein identifiers

PCI domain-containing protein 2 — Q5JVF3 (reviewed: Q5JVF3)

Alternative names: CSN12-like protein

All UniProt accessions (1): Q5JVF3

UniProt curated annotations — full annotation on UniProt →

Function. Required for B-cell survival through the regulation of the expression of cell-cycle checkpoint MAD2L1 protein during B cell differentiation. As a component of the TREX-2 complex, involved in the export of mRNAs to the cytoplasm through the nuclear pores. Binds and stabilizes BRCA2 and is thus involved in the control of R-loop-associated DNA damage and transcription-associated genomic instability. Blocks the activity of the SRCAP chromatin remodeling complex by interacting with SRCAP complex member ZNHIT1 and inhibiting its interaction with the complex. This prevents the deposition of histone variant H2AZ1/H2A.Z at the nucleosomes of key lymphoid fate regulator genes which suppresses their expression and restricts lymphoid lineage commitment.

Subunit / interactions. Component of the nuclear pore complex (NPC)-associated TREX-2 complex (transcription and export complex 2), composed of at least GANP, 2 copies of ENY2, PCID2, SEM1/DSS1, and either centrin CETN2 or centrin CETN3. The TREX-2 complex also associates with ALYREF/ALY and with the nucleoporin NUP153. Interacts with BRCA2. Interacts with SRCAP chromatin remodeling complex component ZNHIT1; the interaction results in inhibition of SRCAP complex activity, preventing the deposition of histone variant H2AZ1/H2A.Z to lymphoid fate regulator genes and restricting lymphoid lineage commitment.

Subcellular location. Cytoplasm. Nucleus. Nuclear pore complex.

Similarity. Belongs to the CSN12 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q5JVF3-1	1	yes
Q5JVF3-2	2
Q5JVF3-3	3
Q5JVF3-4	4

RefSeq proteins (14): NP_001120674, NP_001120675, NP_001245142, NP_001307584, NP_001307585, NP_001307586, NP_001307588, NP_001307589, NP_001340020, NP_001340021, NP_001340022, NP_001340023, NP_001340024, NP_060856 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000717	PCI_dom	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR045114	Csn12-like	Family

Pfam: PF01399

UniProt features (32 total): helix 13, sequence conflict 7, strand 3, splice variant 3, modified residue 2, initiator methionine 1, chain 1, domain 1, turn 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
3T5X	X-RAY DIFFRACTION	2.12
9DLP	ELECTRON MICROSCOPY	2.79
9T6L	ELECTRON MICROSCOPY	2.9
9DLV	ELECTRON MICROSCOPY	2.97
9T6N	ELECTRON MICROSCOPY	3
9DLR	ELECTRON MICROSCOPY	3.08
9UPC	ELECTRON MICROSCOPY	3.14
9UPB	ELECTRON MICROSCOPY	3.41
8R7J	ELECTRON MICROSCOPY	3.5
8R7K	ELECTRON MICROSCOPY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5JVF3-F1	95.64	0.93

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 45

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 213 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_CHROMOSOME_ORGANIZATION, GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_B_CELL_ACTIVATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_NUCLEAR_TRANSPORT, GOBP_REGULATION_OF_LEUKOCYTE_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, GOBP_REGULATION_OF_HEMOPOIESIS, GOBP_NEGATIVE_REGULATION_OF_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, chr13q34, GOBP_REGULATION_OF_B_CELL_DIFFERENTIATION

GO Biological Process (9): post-transcriptional tethering of RNA polymerase II gene DNA at nuclear periphery (GO:0000973), transcription elongation by RNA polymerase II (GO:0006368), protein transport (GO:0015031), poly(A)+ mRNA export from nucleus (GO:0016973), positive regulation of B cell differentiation (GO:0045579), negative regulation of gene expression, epigenetic (GO:0045814), spleen development (GO:0048536), negative regulation of lymphoid progenitor cell differentiation (GO:1905457), mRNA transport (GO:0051028)

GO Molecular Function (3): double-stranded DNA binding (GO:0003690), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), nuclear pore nuclear basket (GO:0044615), transcription export complex 2 (GO:0070390), nuclear pore (GO:0005643), protein-containing complex (GO:0032991)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear protein-containing complex	3
transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery	1
DNA-templated transcription elongation	1
transcription by RNA polymerase II	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
mRNA export from nucleus	1
B cell differentiation	1
regulation of B cell differentiation	1
positive regulation of lymphocyte differentiation	1
positive regulation of B cell activation	1
negative regulation of gene expression	1
epigenetic regulation of gene expression	1
hematopoietic or lymphoid organ development	1
lymphoid progenitor cell differentiation	1
negative regulation of hematopoietic progenitor cell differentiation	1
regulation of lymphoid progenitor cell differentiation	1
RNA transport	1
DNA binding	1
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
nuclear pore	1
nuclear envelope	1
cellular_component	1

Protein interactions and networks

STRING

1606 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PCID2	MCM3AP	O60318	994
PCID2	ENY2	Q9NPA8	991
PCID2	CETN2	P41208	986
PCID2	SEM1	Q6ZVN7	969
PCID2	CETN3	O15182	864
PCID2	BRCA2	P51587	731
PCID2	CUL4A	Q13619	725
PCID2	MAD1L1	Q9Y6D9	670
PCID2	MAD2L1	Q13257	669
PCID2	BUB1B	O60566	655
PCID2	RAE1	P78406	649
PCID2	CCNB1	P14635	588
PCID2	DDB2	Q92466	579
PCID2	ZNHIT1	O43257	570
PCID2	CDK1	P06493	543

IntAct

67 interactions, top by confidence:

A	B	Type	Score
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
SEM1	PCID2	psi-mi:“MI:0915”(physical association)	0.670
CETN1	SFI1	psi-mi:“MI:0914”(association)	0.640
IKZF3	PCID2	psi-mi:“MI:0915”(physical association)	0.560
PCID2	IKZF3	psi-mi:“MI:0915”(physical association)	0.560
PCID2	LENG8	psi-mi:“MI:0915”(physical association)	0.560
NCBP3	SAP18	psi-mi:“MI:0914”(association)	0.530
NS1	PIK3R2	psi-mi:“MI:0914”(association)	0.530
PCID2	espY1	psi-mi:“MI:0915”(physical association)	0.370
NS1		psi-mi:“MI:0914”(association)	0.350
NS1	SAC3D1	psi-mi:“MI:0914”(association)	0.350
NS1	ESYT2	psi-mi:“MI:0914”(association)	0.350
RRP1B	ZNF785	psi-mi:“MI:0914”(association)	0.350
NCBP3	RSL1D1	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
NCBP3	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
NCBP3	SLC27A2	psi-mi:“MI:0914”(association)	0.350

BioGRID (115): PCID2 (Two-hybrid), PCID2 (Affinity Capture-RNA), PCID2 (Affinity Capture-RNA), PCID2 (Affinity Capture-RNA), PCID2 (Two-hybrid), CAPZB (Co-fractionation), DDX3X (Co-fractionation), IMPDH2 (Co-fractionation), LSM1 (Co-fractionation), PCID2 (Co-fractionation), PCID2 (Co-fractionation), PSMD6 (Co-fractionation), SNX2 (Co-fractionation), SNX6 (Co-fractionation), UBE4B (Co-fractionation)

ESM2 similar proteins: A1A5Y5, A1Z6M6, A2ACP1, A7E727, A7SUU7, A8NY27, A8X419, D3ZC96, O13693, O42897, O61820, O94699, P34560, P40515, Q03560, Q09266, Q0VGK2, Q1LXE6, Q20255, Q28D40, Q28DB0, Q2TBN6, Q5AFF7, Q5FWP8, Q5JVF3, Q5SRH9, Q5U3P0, Q5VTQ0, Q5XHH9, Q60YJ7, Q61LA1, Q6BLG8, Q6CU37, Q6FIQ1, Q6INC1, Q7RXQ1, Q7SI58, Q8BFV2, Q8BYY4, Q8C0S4

Diamond homologs: O13873, P0CR48, P0CR49, Q2TBN6, Q4IMN9, Q4P8T5, Q4WJX0, Q5FWP8, Q5JVF3, Q5U3P0, Q6C1L4, Q6CPB1, Q7SD63, Q8BFV2, Q9VTL1, Q54PX7, Q60YJ7, Q8GWE6, Q95QU0, Q9Y820, Q6BGR7, Q75BU2

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 63 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of expression of SLITs and ROBOs	5	8.4×	1e-02
Metabolism of RNA	8	8.1×	2e-03
mRNA Splicing - Major Pathway	6	8.0×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

113 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	69
Likely benign	11
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

2740 predictions. Top by Δscore:

Variant	Effect	Δscore
13:113178960:A:AC	donor_gain	1.0000
13:113178961:C:CC	donor_gain	1.0000
13:113178961:CA:C	donor_gain	1.0000
13:113178961:CACA:C	donor_gain	1.0000
13:113178991:CA:C	donor_gain	1.0000
13:113178997:A:C	donor_gain	1.0000
13:113179000:T:TA	donor_gain	1.0000
13:113179015:T:TA	donor_gain	1.0000
13:113179087:TAC:T	acceptor_gain	1.0000
13:113179087:TACC:T	acceptor_loss	1.0000
13:113179088:ACC:A	acceptor_loss	1.0000
13:113179089:CCTG:C	acceptor_loss	1.0000
13:113179090:C:CC	acceptor_gain	1.0000
13:113179091:T:A	acceptor_loss	1.0000
13:113179911:GCTTA:G	donor_loss	1.0000
13:113179912:CTTAC:C	donor_loss	1.0000
13:113179914:TA:T	donor_loss	1.0000
13:113179915:A:AC	donor_gain	1.0000
13:113179916:C:CT	donor_gain	1.0000
13:113179916:CA:C	donor_gain	1.0000
13:113179916:CACT:C	donor_gain	1.0000
13:113179916:CACTT:C	donor_gain	1.0000
13:113179921:T:A	donor_gain	1.0000
13:113179933:T:TA	donor_gain	1.0000
13:113180039:CTCG:C	acceptor_gain	1.0000
13:113180040:TCG:T	acceptor_gain	1.0000
13:113180041:CG:C	acceptor_gain	1.0000
13:113180041:CGC:C	acceptor_gain	1.0000
13:113180043:C:CA	acceptor_loss	1.0000
13:113180043:C:CC	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000010267 (13:113168752 C>A,T), RS1000055134 (13:113173047 C>T), RS1000108535 (13:113172870 C>A), RS1000120386 (13:113178083 C>T), RS1000141513 (13:113207608 A>G), RS1000184070 (13:113174110 C>T), RS1000215911 (13:113195473 T>G), RS1000227104 (13:113189896 G>A), RS1000240800 (13:113178869 C>G,T), RS1000316205 (13:113195075 T>C), RS1000352417 (13:113178664 T>C), RS1000419789 (13:113184946 G>A), RS1000489504 (13:113207950 G>A,C,T), RS1000504881 (13:113176928 C>G), RS1000574148 (13:113188131 G>A)

Disease associations

OMIM: gene MIM:613713 | disease phenotypes: MIM:614024

GenCC curated gene-disease

Mondo (1): protein Z deficiency (MONDO:0013532)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST004602_174	Mean corpuscular volume	2.000000e-10
GCST004630_196	Mean corpuscular hemoglobin	3.000000e-14
GCST008103_78	Bipolar disorder	1.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725175 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 5 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.05	Kd	90	nM	MOLIBRESIB
6.58	IC50	260	nM	MOLIBRESIB
5.72	Kd	1923	nM	CHEMBL3752910
5.72	ED50	1923	nM	CHEMBL3752910

PubChem BioAssay actives

3 with measured affinity, of 11 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179187: Binding affinity against PCID2 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0900	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148945: Binding affinity to human PCID2 incubated for 45 mins by Kinobead based pull down assay	kd	1.9226	uM

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
Valproic Acid	decreases expression, decreases methylation	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
K 7174	increases expression	1
abrine	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	increases abundance, affects cotreatment, decreases expression	1
Benzo(a)pyrene	increases methylation	1
Cannabidiol	decreases expression	1
Formaldehyde	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Ivermectin	decreases expression	1
Manganese	increases abundance, affects cotreatment, decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Silicon Dioxide	decreases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651987	Binding	Binding affinity to human PCID2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.